The JAK Inhibitors Changing Dermatology

Over the last 13 years, 10 separate therapies under the Janus kinase (JAK) inhibitor drug class have received US Food and Drug Administration (FDA) approval. These agents have predominately reached dermatologic indications, ranging from the more commonly chronic diseases (atopic dermatitis and psoriasis) to the cosmetic-affecting, difficult-to-treat conditions (alopecia areata and vitiligo).